RedHill Biopharma Ltd. (RDHL) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

RedHill Biopharma Ltd. (RDHL) closed at USD 0.50 on 2026-10-15, a change of -65.8 % over the past year, with a market capitalization of USD 4.27M.

RedHill Biopharma Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

RedHill Biopharma Ltd. key figures

Previous close

USD 0.50 (2026-10-15)

1-year change

-65.8 %

Market cap

USD 4.27M

Enterprise value

USD -1.64M

P/E ratio (trailing)

n/a

P/E ratio (forward)

16.00

EPS (trailing)

0.00

EPS (forward)

0.03

PEG ratio

n/a

Price to book

0.57

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.04

Employees

13

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for RedHill Biopharma Ltd. and compare it with other stocks.